Cargando…

Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines

BACKGROUND: At present the mumps virus strain used for production of mumps vaccine for our local use is Hoshino strain. However, according to our National public health policies, this strain should be replaced with a safer strain. Based on our previous data, the Iranian mumps strain; RS-12 has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahkarami, M K, Mokhtari Azad, T, Aghaiypour, K, Shafyi, A, Taqavian, M, Mohammadi, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482322/
https://www.ncbi.nlm.nih.gov/pubmed/23115712
_version_ 1782247855892725760
author Shahkarami, M K
Mokhtari Azad, T
Aghaiypour, K
Shafyi, A
Taqavian, M
Mohammadi, A
author_facet Shahkarami, M K
Mokhtari Azad, T
Aghaiypour, K
Shafyi, A
Taqavian, M
Mohammadi, A
author_sort Shahkarami, M K
collection PubMed
description BACKGROUND: At present the mumps virus strain used for production of mumps vaccine for our local use is Hoshino strain. However, according to our National public health policies, this strain should be replaced with a safer strain. Based on our previous data, the Iranian mumps strain; RS-12 has been proved to be the most suitable alternative to Hoshino strain with little or no adverse events following vaccination METHODS: The aim of the present study was to optimize propagation of RS-12 strain and prepare standard seeds for vaccine mass production. The virus was inoculated to cells using different methods and different multiplicity of infection (MOI). The viral suspensions were harvested using different methods. Quality control tests were run at different stages. RESULTS: Maximum viral yield was achieved when cell suspensions were inoculated at MOI of 1:10 and incubated at 36-37ºC for 48 hours, followed by replacement of the media and incubation at 33-34 ºC for 5-7 days. Filtration did not affect the viral titre. A standard seed lot system was successfully established and experimental batches of MMR vaccines were produced. CONCLUSION: The established seed lot system has met all requirements of WHO regulations and could be used in mass production of safe and efficacious mumps and MMR vaccines. Clinical trials are in progress for this newly produced vaccine.
format Online
Article
Text
id pubmed-3482322
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-34823222012-10-31 Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines Shahkarami, M K Mokhtari Azad, T Aghaiypour, K Shafyi, A Taqavian, M Mohammadi, A Iran Red Crescent Med J Original Article BACKGROUND: At present the mumps virus strain used for production of mumps vaccine for our local use is Hoshino strain. However, according to our National public health policies, this strain should be replaced with a safer strain. Based on our previous data, the Iranian mumps strain; RS-12 has been proved to be the most suitable alternative to Hoshino strain with little or no adverse events following vaccination METHODS: The aim of the present study was to optimize propagation of RS-12 strain and prepare standard seeds for vaccine mass production. The virus was inoculated to cells using different methods and different multiplicity of infection (MOI). The viral suspensions were harvested using different methods. Quality control tests were run at different stages. RESULTS: Maximum viral yield was achieved when cell suspensions were inoculated at MOI of 1:10 and incubated at 36-37ºC for 48 hours, followed by replacement of the media and incubation at 33-34 ºC for 5-7 days. Filtration did not affect the viral titre. A standard seed lot system was successfully established and experimental batches of MMR vaccines were produced. CONCLUSION: The established seed lot system has met all requirements of WHO regulations and could be used in mass production of safe and efficacious mumps and MMR vaccines. Clinical trials are in progress for this newly produced vaccine. Kowsar 2012-09-30 2012-09 /pmc/articles/PMC3482322/ /pubmed/23115712 Text en Copyright © 2012, Iranian Red Crescent Medical Journal http://creativecommons.org/licenses/by/3/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Shahkarami, M K
Mokhtari Azad, T
Aghaiypour, K
Shafyi, A
Taqavian, M
Mohammadi, A
Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines
title Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines
title_full Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines
title_fullStr Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines
title_full_unstemmed Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines
title_short Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines
title_sort establishment of a standard seed lot system of an iranian mumps virus strain; rs-12, for mass production of mumps and mmr vaccines
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482322/
https://www.ncbi.nlm.nih.gov/pubmed/23115712
work_keys_str_mv AT shahkaramimk establishmentofastandardseedlotsystemofaniranianmumpsvirusstrainrs12formassproductionofmumpsandmmrvaccines
AT mokhtariazadt establishmentofastandardseedlotsystemofaniranianmumpsvirusstrainrs12formassproductionofmumpsandmmrvaccines
AT aghaiypourk establishmentofastandardseedlotsystemofaniranianmumpsvirusstrainrs12formassproductionofmumpsandmmrvaccines
AT shafyia establishmentofastandardseedlotsystemofaniranianmumpsvirusstrainrs12formassproductionofmumpsandmmrvaccines
AT taqavianm establishmentofastandardseedlotsystemofaniranianmumpsvirusstrainrs12formassproductionofmumpsandmmrvaccines
AT mohammadia establishmentofastandardseedlotsystemofaniranianmumpsvirusstrainrs12formassproductionofmumpsandmmrvaccines